Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia

N. J. Talley, R. S. Choung, Michael Camilleri, R. A. Dierkhising, A. R. Zinsmeister

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Asimadoline, a kappa-opioid agonist, reduces visceral sensitivity in experimental animal models and may decrease satiation and postprandial fullness in healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored. Aim: To evaluate the effects of asimadoline on satiation volume and postchallenge symptoms in functional dyspepsia. Methods: A randomized, double-blind trial evaluated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n = 13) or 1.0 mg (n = 13) or placebo (n = 14) b.d. in patients with functional dyspepsia (Rome II). Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index were used to assess symptoms during the 8-week treatment. Results: Over 8 weeks of treatment, asimadoline had no significant effect on maximum-tolerated volume or aggregate symptom score with nutrient drink challenge, and on the mean of the total daily symptom severity score compared to placebo. In a post hoc analysis, asimadoline 0.5 mg significantly increased the maximum-tolerated volume (1217 mL ± 90.2) compared to placebo (807 mL ± 111.8) in patients with higher postprandial fullness scores (P = 0.01). Conclusion: Asimadoline overall did not significantly alter maximum-tolerated volume, symptoms postnutrient challenge or symptoms over 8 weeks in functional dyspepsia.

Original languageEnglish (US)
Pages (from-to)1122-1131
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume27
Issue number11
DOIs
StatePublished - Jun 2008

Fingerprint

Satiation
Dyspepsia
Opioid Analgesics
Placebos
asimadoline
Stomach
Animal Models
Food
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. / Talley, N. J.; Choung, R. S.; Camilleri, Michael; Dierkhising, R. A.; Zinsmeister, A. R.

In: Alimentary Pharmacology and Therapeutics, Vol. 27, No. 11, 06.2008, p. 1122-1131.

Research output: Contribution to journalArticle

Talley, N. J. ; Choung, R. S. ; Camilleri, Michael ; Dierkhising, R. A. ; Zinsmeister, A. R. / Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. In: Alimentary Pharmacology and Therapeutics. 2008 ; Vol. 27, No. 11. pp. 1122-1131.
@article{445b512a77504d4db27ba2b9b92e4f3c,
title = "Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia",
abstract = "Background: Asimadoline, a kappa-opioid agonist, reduces visceral sensitivity in experimental animal models and may decrease satiation and postprandial fullness in healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored. Aim: To evaluate the effects of asimadoline on satiation volume and postchallenge symptoms in functional dyspepsia. Methods: A randomized, double-blind trial evaluated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n = 13) or 1.0 mg (n = 13) or placebo (n = 14) b.d. in patients with functional dyspepsia (Rome II). Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index were used to assess symptoms during the 8-week treatment. Results: Over 8 weeks of treatment, asimadoline had no significant effect on maximum-tolerated volume or aggregate symptom score with nutrient drink challenge, and on the mean of the total daily symptom severity score compared to placebo. In a post hoc analysis, asimadoline 0.5 mg significantly increased the maximum-tolerated volume (1217 mL ± 90.2) compared to placebo (807 mL ± 111.8) in patients with higher postprandial fullness scores (P = 0.01). Conclusion: Asimadoline overall did not significantly alter maximum-tolerated volume, symptoms postnutrient challenge or symptoms over 8 weeks in functional dyspepsia.",
author = "Talley, {N. J.} and Choung, {R. S.} and Michael Camilleri and Dierkhising, {R. A.} and Zinsmeister, {A. R.}",
year = "2008",
month = "6",
doi = "10.1111/j.1365-2036.2008.03676.x",
language = "English (US)",
volume = "27",
pages = "1122--1131",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia

AU - Talley, N. J.

AU - Choung, R. S.

AU - Camilleri, Michael

AU - Dierkhising, R. A.

AU - Zinsmeister, A. R.

PY - 2008/6

Y1 - 2008/6

N2 - Background: Asimadoline, a kappa-opioid agonist, reduces visceral sensitivity in experimental animal models and may decrease satiation and postprandial fullness in healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored. Aim: To evaluate the effects of asimadoline on satiation volume and postchallenge symptoms in functional dyspepsia. Methods: A randomized, double-blind trial evaluated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n = 13) or 1.0 mg (n = 13) or placebo (n = 14) b.d. in patients with functional dyspepsia (Rome II). Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index were used to assess symptoms during the 8-week treatment. Results: Over 8 weeks of treatment, asimadoline had no significant effect on maximum-tolerated volume or aggregate symptom score with nutrient drink challenge, and on the mean of the total daily symptom severity score compared to placebo. In a post hoc analysis, asimadoline 0.5 mg significantly increased the maximum-tolerated volume (1217 mL ± 90.2) compared to placebo (807 mL ± 111.8) in patients with higher postprandial fullness scores (P = 0.01). Conclusion: Asimadoline overall did not significantly alter maximum-tolerated volume, symptoms postnutrient challenge or symptoms over 8 weeks in functional dyspepsia.

AB - Background: Asimadoline, a kappa-opioid agonist, reduces visceral sensitivity in experimental animal models and may decrease satiation and postprandial fullness in healthy individuals. However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored. Aim: To evaluate the effects of asimadoline on satiation volume and postchallenge symptoms in functional dyspepsia. Methods: A randomized, double-blind trial evaluated gastric satiation and symptoms before and after 8 weeks of asimadoline 0.5 mg (n = 13) or 1.0 mg (n = 13) or placebo (n = 14) b.d. in patients with functional dyspepsia (Rome II). Gastrointestinal Symptom Rating Scale and Nepean Dyspepsia Index were used to assess symptoms during the 8-week treatment. Results: Over 8 weeks of treatment, asimadoline had no significant effect on maximum-tolerated volume or aggregate symptom score with nutrient drink challenge, and on the mean of the total daily symptom severity score compared to placebo. In a post hoc analysis, asimadoline 0.5 mg significantly increased the maximum-tolerated volume (1217 mL ± 90.2) compared to placebo (807 mL ± 111.8) in patients with higher postprandial fullness scores (P = 0.01). Conclusion: Asimadoline overall did not significantly alter maximum-tolerated volume, symptoms postnutrient challenge or symptoms over 8 weeks in functional dyspepsia.

UR - http://www.scopus.com/inward/record.url?scp=42949157179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949157179&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2008.03676.x

DO - 10.1111/j.1365-2036.2008.03676.x

M3 - Article

VL - 27

SP - 1122

EP - 1131

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 11

ER -